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A B S T R A C T
Rutin, a phenolic compound, has antioxidant, anti-dyslipidaemic, and body weight-
reducing effects. We evaluated the anti-arteriosclerotic, antioxidant, and body weight-
reducing effects of rutin-rich Tartary buckwheat. We randomly divided 144 adult subjects
into an active test food group consuming products containing rutin-rich Tartary buck-
wheat and a placebo food group. Body composition measurements and haematological and
urine tests were performed at weeks 0, 4, 8, and 12, and at 3 weeks after termination. Ath-
erosclerosis index and ox-LDL did not significantly differ between the groups. However,TBARS
levels, BW and BMI in the active test food group were significantly lower than those in the
placebo group at week 8 (p = 0.027, p = 0.030, respectively). BFP in the active test food group
at week 4 (p = 0.038) was lower than that in the placebo group.Thus, rutin-rich Tartary buck-
wheat intake may be effective for body weight due to its antioxidant properties.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Rutin is a flavonoid of the flavonol type, which is commonly
found in plants (Al-Dhabi, Arasu, Park, & Park, 2015;
Tranchimand, Brouant, & Iacazio, 2010). Rutin shows antioxi-
dant effects via scavenging of radiation-induced free radicals
(Carrasco-Pozo, Mizgier, Speisky, & Gotteland, 2012; Patil, Rao,
Somashekarappa, & Rajashekhar, 2014). In addition, it has
several pharmacological functions such as anti-inflammatory,
anti-diabetic, and blood capillary strengthening properties
(Chua, 2013; Griffith, Couch, & Lindauer, 1944; Shanno, 1946).
Kamalakkannan and Prince (2006) reported that oral admin-
istration of rutin decreased blood glucose levels and increased
insulin secretion in streptozotocin-induced diabetic rats. Other
reports suggested that oral administration of rutin signifi-
cantly decreased the levels of lipids in plasma and tissues in
streptozotocin-induced diabetic rats (Stanely Mainzen Prince
& Kannan, 2006). In addition, rutin has cardioprotective effects
(Annapurna, Reddy, Akondi, & Rao, 2009), which are related to
its ability to inhibit platelet aggregation (Pace-Asciak, Hahn,
Diamandis, Soleas, & Goldberg, 1995). Although it has been re-
ported that rutin has several pharmacological effects, its exact
mechanism and metabolism were not fully elucidated.
Buckwheat is recognised as a functional food and a good
source of nutritionally valuable amino acids (Jiang et al., 2007),
dietary fibres (Bonafaccia, Marocchini, & Kreft, 2003), andmin-
erals such as zinc and copper (Ikeda & Yamashita, 1994). In
particular,Tartary buckwheat (Fagopyrum tataricumGaertn.) con-
tains approximately 100-foldhigher amounts of rutin in its seeds
compared to commonbuckwheat (Fabjan et al., 2003;Morishita,
Yamaguchi, &Degi, 2007). In a double-blind clinical trial, 2-week
intake of Tartary buckwheat cookies with high rutin content
(360 mg/day) decreased levels of total cholesterol (TC) and
myeloperoxidase,an antioxidantmarker, as compared toTartary
buckwheat cookies with low rutin content (17 mg/day)
(Wieslander et al., 2011). This finding suggests that rutin-rich
Tartary buckwheat can display beneficial functions, including
anti-atherosclerotic and antioxidant effects. However, Tartary
buckwheat contains a high level of rutinosidase, which hy-
drolyses rutin (Suzuki, Honda, Funatsuki, & Nakatsuka, 2002;
Yasuda, Masaki, & Kashiwagi, 1992; Yasuda &Nakagawa, 1994).
Thus, rutin inTartary buckwheat is hydrolysed in a fewminutes
upon addition of water. Hydrolysis of rutin may diminish its
beneficial functions and give a bitter taste. These facts have
limited the use of Tartary buckwheat in food products.
A new variety of rutin-rich Tartary buckwheat ‘Manten-
Kirari’ containing only trace amounts of rutinosidase has been
developed by the NARO Hokkaido Agricultural Research Center
(Suzuki et al., 2014). Therefore, most of rutin remains
unhydrolysed, and products developed from ‘Manten-Kirari’,
show high hydrophilic antioxidant capacity (H-ORAC) (Ishiguro,
Morishita, Ashizawa, Suzuki, & Noda, 2016).These facts suggest
that consumption of Manten-Kirari can provide rutin in suf-
ficient amounts to perform its biological functions and at the
same time, avoiding the bitter taste.
To investigate whether consumption of rutin-rich Tartary
buckwheat could reduce arteriosclerosis, display antioxidant
effects, and change body composition, we conducted this
double-blind, placebo-controlled study.
2. Material and methods
2.1. Preparation of rutin-rich Tartary buckwheat
A variety of Tartary buckwheat, ‘Manten-Kirari’, cultivated in
Hokkaido, Japan, was used for preparation of the active test
food in this trial. Hard wheat flour prepared from ‘Yumechikara’
was used for formulation of the placebo food. The active test
food was manufactured and packed under strict quality control
at the plant of Kobayashi Shokuhin Co., Ltd. (Hokkaido, Japan)
in compliance with the Food Sanitation Act (Ministry of Health,
Labour, and Welfare of Japan). The manufacturing process of
buckwheat noodles included the following (in that order):
mixing of the raw materials (Active test foods: ‘Manten-
Kirari’ buckwheat flour 50%, ‘Yumechikara’ wheat flour 47%,
wheat albumin 3%; placebo foods: ‘Yumechikara’ wheat flour
97% and wheat albumin 3%), addition of some water, prepa-
ration of primary noodle dough, pressing to prepare noodle
sheets, cutting, casing, and drying.The manufacturing process
of cookies included the following (in that order): mixing of the
raw materials (Active test cookies: ‘Manten-Kirari’ buck-
wheat flour 50.4%, beet sugar 17.2%, egg 25.9%, butter 6.2% and
salt 0.3%; Placebo cookies: “Yumechikara’ wheat flour 50.4%,
beet sugar 17.2%, egg 25.9%, butter 6.2% and salt 0.3%), shaping
with cookie cutter, and baking in oven. Although the
rutinosidase activity in ‘Manten-Kirari’ is lower than those in
other varieties (the rutinosidase activity, ‘Manten-Kirari’: other
varieties = 1:1000), ‘Manten-Kirari’ contains trace amounts of
rutinosidase. Therefore, the rutin in the dough gradually hy-
drolysed upon addition of water.The degree of rutin hydrolysis
increases with the increase in the dough water concentra-
tion, temperature and ratio of Tartary buckwheat flour in the
dough (Suzuki, Morishita, Takigawa, Noda, & Ishiguro, 2015b).
For example, more than 90% of rutin remained in ‘Manten-
Kirari’ whereas the majority of rutin was hydrolysed in other
varieties within 30 minutes after addition of water. To reduce
rutin hydrolysis, it is very important to shorten the process-
ing time from water addition to drying. In this study, casing
was completed within 40 minutes after water addition, and raw
noodles were immediately dried to decrease the water con-
centration. As a result, we obtained rutin-rich noodles and
cookies. Nutrition facts regarding the active test food and
placebo food used in this study are provided in Table 1. Rutin
concentration in the test food and placebo food was mea-
sured using HPLC. Briefly, 1.0 g of rutin-containing sample was
extracted with a mixture of 7.2 mL of methanol and 1.8 mL of
0.1% phosphoric acid at 80 °C for 2 hours (Suzuki et al., 2002).
After extraction, the sample was centrifuged at 5000 g for 10
minutes, and the resultant supernatant was filtered through
a 0.45-mm filter and assayed using HPLC. HPLC was per-
formed using a Cadenza CD-C18 column (Imtakt, Japan) at a
flow rate of 0.2 mL/min.The elution gradient program was set
at 0–20 min with isocratic flow conditions at solvent A
[acetonitrile–water–TFA (7.5:92.2.7:0.3)]: solvent B [acetonitrile–
water–TFA (55:44.7:0.3)] as 63:37. The chromatogram was
visualised at 360 nm. According to the study design, subjects
should take 500 mg of rutin every day from the active test food.
However, since about 20% of rutin would be lost during the
boiling process, therefore, we adjusted the content of rutin in
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the dry noodles at more than 500 mg.The active test food and
the placebo food were identical in appearance. Previous reports
suggested that a dose of 5000 mg flour/kg bodyweight was the
No Observed Adverse Effect Level (NOAEL) determined by in
vivo acute and subacute toxicology studies (Suzuki, Morishita,
Noda, & Ishiguro, 2015a).
2.2. Study subjects
We recruited 231 volunteers, of whom 230 provided written in-
formed consents to participate in this clinical study. Finally,
we selected 149 subjects (42 males and 107 females aged 30–
69 years; atherosclerosis-index (AI), 2.25 ± 0.65) through a
screening test, excluding the following: individuals with a recent
history of gastrointestinal disorders; pregnancy; severe acute
or chronic diseases; surgery; severe allergic reaction to food,
particularly buckwheat and wheat, and/or current use of any
medications including anti-hyperlipidaemic medications.These
149 eligible subjects were randomly assigned to either the active
test food (n = 74) or the placebo food group (n = 75), with ad-
justments for age, sex, and AI. The randomised allocation
sequence was created using a permuted-block randomisation
design stratified by age, gender, and AI, where the block size
was a multiple of two. Each subject was allocated by a third-
party data centre according to the random allocation sequence
into a relevant group. The third-party data centre concealed
the allocation information, including the subjects’ personal data,
and kept them secure.This information was disclosed only after
the laboratory and analytical data were fixed, and the method
of statistical analysis was finalised.
2.3. Study design
The clinical study was conducted as a double-blind, placebo-
controlled trial. The time schedule for the study is shown in
Fig. 1. We performed body composition measurements, in-
cluding body weight (BW), body mass index (BMI), and body
fat percentage (BFP) analyses, at weeks 0 (baseline), 4, 8, and
12 after the start of rutin ingestion, and 3 weeks after the end
of rutin ingestion. At all five time points, a medical interview
was conducted along with a check of the vital signs and
haematological and urine tests.We asked the subjects to take
80 g (dry weight) of the active test noodles or placebo noodles
per day at any time of the day and cook them using any cooking
method they liked. When the subjects could not cook the
noodles, they were allowed to consume cookies instead for up
to 2 days per week. During the course of this study, subjects
were asked to not change their daily activities, including food
consumption, medications, and exercises. The primary out-
comes were AI and oxidised LDL (ox-LDL) levels.The secondary
outcomes were the thiobarbituric acid reactive substance
(TBARS), urinary 8-hydroxy-2′-deoxyguanosine (urinary 8-OHdG),
TC, high-density lipoprotein cholesterol (HDL-C), and low density
lipoprotein cholesterol (LDL-C) levels, BW, BFP, and BMI.
2.4. Physical and haematological examinations
Blood samples were collected at the following time points: base-
line, at weeks 4, 8, and 12 after the start of rutin ingestion and
at 3 weeks after the end of rutin ingestion. In addition to a
medical interview, each subject’s body composition (BW, BMI,
and BFP) and blood pressure (BP) weremeasured. Subjects fasted
for 12 hours before blood collection. General blood tests were
Table 1 – Nutrition facts pertaining to the rutin-rich
Tartary buckwheat (Manten-Kirari) foods and the
placebo (Yumechikara) foods.
Active test food
prepared from
rutin-rich Tartary
buckwheat
(‘Manten-Kirari’)
Placebo food
prepared from
hard wheat flour
(‘Yumechikara’)
Noodles
(80g dry
weight)
Cookies
(50 g)
Noodles
(80 g dry
weight)
Cookies
(50 g)
Calories (kcal) 280 190 280 207
Water (g) 9.7 8.2 9.4 4.3
Proteins (g) 12.7 5.8 13.0 7.1
Lipids (g) 2.1 5.6 1.3 5.4
Carbohydrates (g) 51.4 28.4 53.1 31.9
Ash (g) – – – –
Sodium (mg) 434 97 382 107
Rutin (mg) 619.8 321.1 0 0
Analysis methods: Calories were calculated by formula: proteins
(g/100g) × 4 kcal/g + lipids (g/100g) × 9 kcal/g + carbohydrates
(g/100g) × 4 kcal/g + fibre (g/100g) × 2 kcal/g; Water, atmospheric
heat drying method; protein, Kjeldahl method; lipid, acid
digestion; carbohydrates were calculated by formula:
100 − (water + protein + lipid + ash + fiber); ash, direct ashing method;
sodium, atomic absorption analysis method.
Fig. 1 – Time course of this clinical study.
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performed antioxidant markers (ox-LDL andTBARS), lipid profile
(AI, TG, TC, HDL-C, and LDL-C), complete blood count [CBC;
white blood cells (WBC), red blood cells (RBC), haemoglobin
content (Hb), haematocrit value (Ht), and platelet count (Plt)],
liver function [aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), gamma-glutamyl transpeptidase (γ-
GTP), alkaline phosphatase (ALP), and lactate dehydrogenase
(LDH)], and kidney function [blood urea nitrogen (BUN), cre-
atinine (Cr), and uric acid (UAC)], and urine tests including
8-OHdG levels were measured.
Haematological tests were performed at Sapporo Clinical
Laboratory, Inc. (Sapporo, Japan). Ox-LDL andTBARS were mea-
sured using ox-LDL ELISA kit (Sekisui Medical Co., Ltd., Tokyo,
Japan) andTBARS assay kit (Cayman Chemical, Michigan, USA).
TG, TC, HDL-C, and LDL-C were measured by free glycerol
method, cholesterol oxidase method, selective inhibition
method and selective solubilisation method. AI was calcu-
lated in LDL-C/HDL-C.WBC, RBC, Hb, Ht, and Plt were measured
by flow cytometry method, electrical resistivity measure-
ment, SLS-Hb method and electrical resistivity measurement.
AST, ALT, γ-GTP, ALP, and LDH were measured by Japan Society
of Clinical Chemistry (JSCC) reference method. BUN, Cr, and
UAC were measured by urease-GLDH method, enzyme assay
and uricase-POD method. 8-OHdG was measured by New
8-OHdG Check Elisa (Japan Institute for the Control of Aging,
NIKKEN SEIL. CO., Ltd., Shizuoka, Japan) and corrected for cre-
atinine concentrations. Each subject’s body composition and
BP were measured using a Body Composition Analyzer DC-
320 (Tanita Corp,Tokyo, Japan) and anAutomatic Blood Pressure
Monitor HEM-7080IC (Omron Colin Co., Ltd., Tokyo, Japan).
2.5. Ethics committee
All subjects provided written informed consent prior to un-
dergoing any of the tests related to this study.The study protocol
was approved by the Ethics Committee of Hokkaido Informa-
tion University in conformity with the Helsinki Declaration (No.
2014-17, date of approval: 27 October 2014).This study was reg-
istered in UMIN (No. UMIN000015682).
2.6. Sample size
The sample size was statistically determined to obtain a power
of 80% with an alpha error of 0.05. In order to demonstrate the
postulated change in AI at week 12 (0.36 reduction with a stan-
dard deviation of 0.70), a sample size of 120 (60 in the test group
and 60 in the placebo group) was required. Assuming a 20%
loss to follow-up, 149 subjects were included.
2.7. Statistical analysis
Mean and standard deviation were calculated for each group.
Changes in the subject values were analysed using repeated
measures ANOVA between the groups. In addition, changes in
the subject values were analysed using Student’s t-test to
compare the mean of the active test food group and placebo
food group at each evaluation point. Statistical analyses were
performed using SPSS Statistics 19 (IBM, Armonk, NY, USA).
p < 0.05 was considered as significant, and p < 0.10 was con-
sidered as marginally different.
3. Results
3.1. Dropouts, exclusions, and characteristics of the
subjects
During the trial, 4 subjects dropped out for personal reasons
(n = 4). As a result, 145 subjects completed this trial, 73 in the
active test food group and 72 in the placebo group. One person
in the placebo group was excluded from the analysis because
of low ingestion rate (<80%). As a result, 144 persons (73 in the
active test food group and 71 in the placebo group) were in-
cluded in the final analysis. The study flow diagram is shown
in Fig. 2. Mean age, height, BW, BMI, BFP, AI, and LDL-C for each
group are presented in Table 2. No significant differences existed
between the active test food and the placebo food groups,
showing appropriate assignment of subjects into the two
groups.
3.2. Effect of rutin-rich Tartary buckwheat on
atherosclerosis-index and oxidised LDL
First, we evaluated the effect of rutin-rich Tartary buckwheat
on AI and ox-LDL (Fig. 3 and Table 3). Table 3 shows that the
interaction of group by time did not differ significantly between
the groups. In addition, there was no significant difference
between the active test food and the placebo food group in the
change in AI levels from the baseline to evaluation points
(Fig. 3A). Moreover, ox-LDL decreased at week 8 in the placebo
food group compared to the active test food group (change in
level from baseline to week 8, placebo: −6.70 ± 25.50 U/L, test:
2.88 ± 24.81 U/L, p = 0.024) (Fig. 3B).
3.3. Effect of rutin-rich Tartary buckwheat on oxidative
stress markers
We also examined the effect of rutin-rich Tartary buckwheat
on oxidative stress markers (Fig. 3 and Table 3). Urinary 8-OHdG
did not differ between the groups (Fig. 3D). However, TBARS
levels significantly decreased at week 8 in the active test food
group (change in level from baseline to week 8, placebo:
0.86 ± 3.95 µM, test: −0.56 ± 3.62 µM, p = 0.027) (Fig. 3C).
3.4. Effect of rutin-rich Tartary buckwheat on lipid
metabolism
We also evaluated the effect of rutin-rich Tartary buckwheat
on lipid metabolism parameters.TC, LDL-C and HDL-C did not
differ between the groups. The group × time interaction gave
marginally significant difference toTG levels (p = 0.072) (Table 3).
However, there were no differences between the active test
group and placebo group in the changes inTG levels from base-
line to each evaluation points.
3.5. Effect of rutin-rich Tartary buckwheat on body
composition
To determine the effect of rutin-richTartary buckwheat on body
composition, we evaluated the changes in BW, BMI, and BFP.
No significant differences in the interaction of group by time
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of BW, BMI, and BFP (Table 4) were observed between the groups.
However, the ingestion of the active test food significantly de-
creased BW and BMI at week 8 (change level in BW from
baseline to week 8, placebo: 0.02 ± 1.18 kg, test: −0.35 ± 0.82 kg,
p = 0.030) (change level in BMI from baseline to week 8, placebo:
0.02 ± 0.44 kg/m2, test: −0.14 ± 0.32 kg/m2, p = 0.016) (Fig. 4A and
C). Moreover, BFP significantly decreased in the active test food
group compared to the placebo food group at week 4 (change
level in BFP from baseline to week 4, placebo: 0.36 ± 1.07%, test:
−0.30 ± 2.39%, p = 0.038) (Fig. 4B).
3.6. Safety
We evaluated the CBC, liver and renal function, and BP after
the ingestion of rutin-richTartary buckwheat products. Minimal
changes were observed in the CBC parameters (WBC, RBC, Hb,
Ht, and Plt), liver function (ALP, AST,ALT, LDH, and γ-GTP), renal
function (BUN, creatinine, and UAC), and BP (Supplementary
Table S1). Although few subjects showed adverse events (head-
ache (n = 40), runny nose/nasal congestion (n = 18), fever (n = 18),
pharyngeal pain (n = 18), cough (n = 17)), their symptoms were
mild, and they recovered in a few days. Thus, the principal
investigator judged that there were no adverse events related
to the ingestion of the test food. These results suggested
that the ingestion of rutin-rich Tartary buckwheat (Manten-
Kirari) had no or minimal unfavourable effects even at a dose
of 50 g/day (as buckwheat flour).
4. Discussion
The results of our randomised, double-blind, placebo-controlled,
parallel-group trial confirmed the potential effects of rutin-
rich Tartary buckwheat, ‘Manten-Kirari’ on lipid metabolism,
antioxidation, and body composition. There were no signifi-
cant differences inAI and ox-LDL levels, and in lipidmetabolism
parameters between the active test food and the placebo food
groups. However, TBARS levels decreased in the test group. In
addition, the ingestion of the active test food decreased BW,
BMI and BFP.
Previous reports indicated that 22-day-continuous inges-
tion of rutin decreased TBARS levels in a dose-dependent
Fig. 2 – Flow diagram of the present study.
Table 2 – Characteristics of the subjects in the active test
food and the placebo food group.
Characteristic Active test
food group
Placebo
food group
p-
value
Subjects, n 73 71 –
Males, n (%) 21 (30.00%) 20 (31.25%) 0.937
Age, years 54.58 ± 9.06 53.66 ± 8.78 0.540
Height, cm 161.22 ± 7.74 159.27 ± 7.19 0.120
Body weight, kg 57.91 ± 10.9 56.73 ± 10.59 0.510
Body fat percentage, % 27.71 ± 6.73 27.76 ± 7.09 0.968
Body mass index, kg/m2 22.18 ± 3.12 22.25 ± 3.30 0.886
Arteriosclerosis index 2.18 ± 0.57 2.32 ± 0.73 0.193
LDL cholesterol, mg/dL 153.21 ± 26.21 152.30 ± 27.42 0.839
Intake rate, % 98.90 ± 3.04 98.70 ± 2.99 0.386
Values shown are mean ± standard deviation. Student’s t-test was
performed for age, height, body weight, body fat percentage, body
mass index, atherosclerosis index and LDL cholesterol. Chi-square
test was performed for gender and Mann–Whitney U test for intake
rate. n = number of subjects.
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manner (from 10 mg/kg to 1000 mg/kg) in rats, although it af-
fected neither the level of lipidmetabolism parameters in serum
and liver nor the level of steroid excretion into faeces
(Nakamura, Ishimitsu, & Tonogai, 2000). In addition, 5-week-
continuous ingestion of 100 mg/kg rutin improved diabetic
neuropathy and decreased TBARS levels in diabetic rat models
(Ola et al., 2015). It was suggested that the antioxidant mecha-
nism of flavonoids, such as rutin, involves radical scavenging
activity (Carrasco-Pozo et al., 2012; Patil et al., 2014). Free radi-
cals that are formed through the auto-oxidation of unsaturated
lipids in plasma and membrane lipids, react with polyunsatu-
rated fatty acids, and lead to lipid peroxidation (detected
by TBARS) (Belguith-Hadriche et al., 2016). Our clinical study
suggested that rutin-rich Tartary buckwheat had antioxidant
effects. However, ox-LDL decreased at week 8 in the placebo
food group compared to the active test food group. This may
Fig. 3 – Changes in atherosclerosis index (AI) and antioxidant markers level from the baseline and each time point. Black
bar: placebo, grey bar: rutin-rich Tartary buckwheat. Values are shown as mean ± standard error (SEM). (A) AI, and (B)
oxidised LDL (ox-LDL), (C) thiobarbituric acid reactive substance level (TBARS) and (D) urinary 8-hydroxy-2′-deoxyguanosine
level corrected for creatinine concentration (8-OHdG). *p < 0.05, #p < 0.10.
Table 3 – Change in lipid metabolism parameters and oxidative stress markers, and body composition after ingestion of
‘Manten-Kirari’ or placebo food.
Change in value
at week 4
Change in value
at week 8
Change in value
at week 12
Change in value
at week 15
p-valuea
AI Placebo −0.06 ± 0.32 −0.08 ± 0.30 −0.04 ± 0.33 −0.07 ± 0.32 0.862
Active −0.01 ± 0.25 0.01 ± 0.26 0 ± 0.31 −0.01 ± 0.30
p-valueb 0.251 0.071# 0.486 0.244
Ox-LDL (U/L) Placebo 3.91 ± 28.64 −6.70 ± 25.50 7.31 ± 30.05 0.24 ± 32.35 0.144
Active 4.38 ± 29.98 2.88 ± 24.81 8.99 ± 23.20 −1.92 ± 30.79
p-valueb 0.924 0.024* 0.71 0.682
TBARS (µM) Placebo 0.24 ± 3.71 0.86 ± 3.95 −0.22 ± 4.04 0.92 ± 4.46 0.288
Active −0.08 ± 4.86 −0.56 ± 3.62 −0.61 ± 3.48 0.19 ± 4.18
p-valueb 0.655 0.027* 0.533 0.315
Urinary 8-OHdG Placebo – – −1.91 ± 3.50 – –
Active – – −1.25 ± 3.10 –
p-valueb – – 0.583 –
TC (mg/dL) Placebo −9.30 ± 22.11 −8.94 ± 20.67 −9.45 ± 22.55 −3.20 ± 23.03 0.683
Active −5.95 ± 21.12 −4.58 ± 20.53 −5.11 ± 23.35 −2.52 ± 21.58
p-valueb 0.355 0.205 0.262 0.856
HDL-C (mg/dL) Placebo −1.23 ± 6.37 −2.08 ± 6.67 −1.20 ± 8.80 1.03 ± 8.43 0.415
Active −1.19 ± 7.24 −1.79 ± 7.55 −0.27 ± 8.47 −0.53 ± 7.53
p-valueb 0.974 0.808 0.522 0.242
LDL-C (mg/dL) Placebo −6.01 ± 20.47 −8.37 ± 19.55 −4.58 ± 21.42 −1.66 ± 19.61 0.216
Active −2.73 ± 18.91 −3.33 ± 18.71 −1.21 ± 19.87 −1.88 ± 19.35
p-valueb 0.32 0.116 0.333 0.947
TG (mg/dL) Placebo 3.57 ± 37.57 20.11 ± 90.78 9.56 ± 48.58 0.10 ± 41.60 0.072#
Active 4.97 ± 33.47 8.59 ± 32.78 3.08 ± 35.16 10.32 ± 37.61
p-valuea 0.877 0.295 0.438 0.211
AI, atherosclerosis-index; Ox-LDL, oxidised LDL; TBARS, thiobarbituric acid reactive substance; 8-OHdG, urinary 8-hydroxy-2′-deoxyguanosine;
TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triacylglycerol. Values are ex-
pressed as mean ± standard division.
Statistically significant, *p < 0.05, marginally significant, #p < 0.10.
a Changes in subject values were analysed using repeated measures ANOVA between the groups.
b Changes in subject values were analysed using Student’s t-test to compare the mean of the active test food group and the placebo food group
at each evaluation point.
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be attributed to a higher initial level of ox-LDL in the placebo
food group compared to that in the active test food group (actual
level of ox-LDL at week 0, test: 129.32 ± 33.18 U/L, placebo:
140.44 ± 37.01 U/L, p = 0.059). In addition, ox-LDL was posi-
tively correlated with serum LDL-C levels (Kondo et al., 2003).
Since serum LDL-C decreased by a higher value in the placebo
food group compared to the active test food group, the ox-
LDL level decreased by a higher magnitude in the placebo group.
Moreover, no significant difference was observed in the ox-
LDL/LDL ratio between the two groups. The underlying cause
is not clear; however, it is generally considered that the fla-
vonoid glycoside rutin is hydrolysed by the intestinal microflora
(Kühnau, 1976). Metabolites containing a vicinal hydroxyl struc-
ture such as quercetin, 3,4-dihydroxyphenylacetic acid (3,4-
DHPAA) and 3,4-dihydroxytoluene (3,4-DHT) play important
roles in the antioxidant effects of rutin (Chua, 2013). It is well
known that Tartary buckwheat contains other functional com-
pounds such as vitamins B1, B2, and B6 and proteins (Guo, Zhu,
Zhang, & Yao, 2010); however, the interaction between rutin
and these compounds was not fully investigated. Since the
metabolic pathways of rutin in Manten-Kirari and that of refined
rutin are different, it is assumed that their metabolites and
effects may also be different. Therefore, further research is re-
quired on the antioxidant effects of ‘Manten-Kirari’ and rutin
metabolites present in ‘Manten-Kirari’ in vivo and in vitro using
purified rutin as a control.
Nosignificantdifferences in lipidmetabolismparameters such
asTC,HDL-C, LDL-C, andTG existed between the active test food
group and the placebo food group.However, the ingestion of the
active test food significantly decreased BW and BMI at week 8.
In addition,BFP decreased atweek 4 in the active test food group
compared to the placebo food group. A previous study has re-
ported that the ingestion110mgquercetin for 12weeksdecreased
visceral fat area in subjects whose BMI was between 25 kg/m2
and 30 kg/m2 (Egawa et al., 2012).Themechanismbywhichquer-
cetin caused visceral fat area improvement was suggested as
inhibition of the gene expression of peroxisome proliferator-
activated receptor gamma (PPARγ) and sterol regulatory element-
binding protein 1c (SREBP-1c) (Eseberri,Miranda, Lasa, Churruca,
& Portillo, 2015) and facilitation of gene expression of proteins
involved inβ-oxidation (Kobori,Masumoto,Akimoto,&Oike, 2011),
as well as inhibition of the mitogen-activated protein kinase
(MAPK) signalling factors extracellular signal-regulated kinase
(ERK)1/2, Jun-N-terminalkinase (JNK),andp38MAPK inadipocytes
and macrophages (Seo, Lee, Hwang, Kim, & Lee, 2015a). Rutin
caused improvement of BW and BFP in rats fed with a high-fat
Table 4 – Change in body composition after ingestion of ‘Manten-Kirari’ or placebo food.
Change in value
at week 4
Change in value
at week 8
Change in value
at week 12
Change in value
at week 15
p-valuea
BW (kg) Placebo −0.01 ± 0.90 0.02 ± 1.18 −0.03 ± 1.46 −0.15 ± 1.50 0.240
Active −0.17 ± 0.73 −0.35 ± 0.82 −0.32 ± 0.87 −0.39 ± 1.09
p-valueb 0.244 0.030* 0.154 0.279
BFP (%) Placebo 0.36 ± 1.07 0.21 ± 1.15 0.29 ± 1.32 −0.10 ± 1.43 0.164
Active −0.30 ± 2.39 0.11 ± 1.10 0.04 ± 1.27 −0.36 ± 1.26
p-valueb 0.038* 0.584 0.250 0.241
BMI (kg/m2) Placebo 0.01 ± 0.34 0.02 ± 0.44 0 ± 0.55 −0.05 ± 0.57 0.286
Active −0.07 ± 0.27 −0.14 ± 0.32 −0.13 ± 0.33 −0.15 ± 0.41
p-valueb 0.133 0.016* 0.098# 0.233
BW, body weight; BFP, body fat percentage; BMI, body mass index. Values are expressed as mean ± standard division.
Statistically significant, *p < 0.05, marginally significant, #p < 0.10.
a Changes in subject values were analysed using repeated measures ANOVA between the groups.
b Changes in subject values were analysed using Student’s t-test to compare the mean of the active test food group and the placebo food group
at each evaluation point.
Fig. 4 – Changes in body composition from the baseline at each time point. Black bar: placebo; grey bar: rutin-rich Tartary
buckwheat. Values are shown as mean ± standard error (SEM). (A) Body weight (BW), (B) body fat percentage (BFP), (C) body
mass index (BMI). *p < 0.05, #p < 0.10.
466 J o u rna l o f Func t i ona l F ood s 2 6 ( 2 0 1 6 ) 4 6 0 – 4 6 9
diet through induction of gene expression related to and acti-
vation of 5′ AMP-activated protein kinase (AMPK) in skeletal
muscles and mitochondrial biosynthesis (Seo et al., 2015b). In
addition, another report suggested thatmRNAexpressions such
as PPARγandCCAAT/enhancer bindingprotein-α (C/EBPα) in 3T3-
L1 cellswere down regulated by rutin treatment (Choi, Park, Choi,
& Lee, 2006).These facts suggested that improvement of BWand
BFP due to the ingestion of ‘Manten-Kirari’ was related to the
activation of AMPK and increase in the energy conversion, and
would regulate the expressionof adipogenic transcription factors
in adipocyte. The effect of BW-reduction by the ingestion of
‘Manten-Kirari’ was limited in our clinical study. However, the
mean of BMI in our subjects was 22.2 kg/m2, and it was re-
garded as non-obese. Therefore, we expected that ingestion of
‘Manten-Kirari’ might more reduce BW and BFR in obese sub-
jects. On the other hand, in the placebo food group, the change
value inTBARS levels frombaseline toweek 8 significantly dem-
onstrated positive correlation with the change value in BMI
(Pearson’s correlation: r = 0.278,p = 0.019); however, in the active
test food group, the change value inTBARS levels did not show
positive correlation with the change value in BMI (Pearson’s
correlation: r = −0.036, p = 0.764). These results suggested that
‘Manten-Kirari’ suppressed the increase in oxidative stress
induced by the increase in BMI. Obesity contributed oxidative
stress and inflammation (Garcés-Rimónet al., 2016; Keaney et al.,
2003; Ramos, Shintani, Ikizler, & Himmelfarb, 2008). It was re-
ported that therewas a significant positive association between
BMI or waist/hip ratio and urinary levels of 8-epi-prostaglandin
F2α (Keaney et al., 2003). The adipose tissue in obesity in-
creased oxidative stress via the increase of NADPH oxidase, the
enzyme production of reactive oxygen species (ROS), and the
reduction of antioxidant enzyme, such as superoxide dismutase
(SOD),glutathioneperoxidaseandcatalase (Furukawaet al., 2004).
Rutin treatment to high-fat diet-fed rats showed not only the
weight reduction of body, liver organ and adipose tissue but also
the reduction of TBARS levels (Hsu, Wu, Huang, & Yen, 2009).
On the other hand, secretion defect of adipokine, such as tumor
necrosis factor-1 (TNF-α),monocyte chemoattractant protein-1
(MCP-1), leptin andadiponectin,were observed in obesity (Freitas
Lima et al., 2015). Rutin also inhibited the expression of leptin
and thenup-regulated theexpressionofadiponectinat theprotein
level in 3T3-L1 adipocytes (Hsu et al., 2009).Moreover, oxidative
stress couldbealso related toadipokine imbalance (Décordéet al.,
2009). Therefore, the inhibition of TNF-α secretion and the in-
crease of adiponectin secretion and leptin sensitivity related to
antioxidant effects may improve obesity through inhibition of
inflammation, improvementof insulin resistance (Kadowaki et al.,
2006; Ye, 2013), or correctness for imbalance between
food intake and energy expenditure (Jung & Choi, 2014) .These
facts suggested that rutin might have directly or indirectly
improved adipokine imbalance, and then reduced BW and
BFR.
In conclusion, the results of this study revealed that
rutin-rich Tartary buckwheat, ‘Manten-Kirari’, showed poten-
tial effects on decreasing BW, BFP, and oxidative stress.
Although additional studies are still needed to elucidate
the molecular mechanisms underlying these effects and to
confirm the results of this study, the present study facilitates
the development of new applications of processed foods
using “Manten-kirari”.
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